Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00382161|
Recruitment Status : Withdrawn (not enough patients meeting inclusion criteria)
First Posted : September 28, 2006
Last Update Posted : February 13, 2009
|Condition or disease||Intervention/treatment||Phase|
|Impotence||Drug: Fluvastatin-sodium||Phase 3|
Physiology of erection is mainly dependent on endothelial NO-production with consecutive activation of guanylate-cyclase. Pleiotropic effects of statins are well known regarding the increase of endothelial function. Thus, activation of endothelial NO-synthase could raise the activation of guanylate-cyclase with a consecutive relaxation of smooth muscle cells in the penile arteries and the corpus cavernosum leading to an improvement of erectile function. Therefore, statins are supposed to be effective in the treatment of erectile dysfunction, especially in patients with cardiovascular risk-factors with underlying endothelial dysfunction.
The effect of fluvastatin on penile blood-flow and erectile function in patients with arteriogenic erectile dysfunction and cardiovascular risk factors will be determined in a cross-over design. Patients were either treated with fluvastatin-sodium 80mg or placebo for 8 weeks. After a wash-out of 4 weeks, treatment will be switched (placebo / fluvastatin-sodium). Penile blood flow measurement and assessment of erectile function with the IIEF-5-score and the KEED-score will be performed at baseline, after 8 weeks of treatment, after 4 weeks wash-out and after cross-over treatment (8 weeks).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction|
|Study Start Date :||October 2006|
|Estimated Study Completion Date :||December 2007|
- Penile blood flow (peak systolic velocity, resistance index, pulsatility index) after 8 weeks of treatment.
- Erectile function assessed with the IIEF-5 score (international index of erectile function) after 8 weeks of treatment.
- Erectile function assessed with the KEED score (cologne questionnaire of erectile function) after 8 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382161
|University Hospital of the Saarland|
|Homburg, Saarland, Germany, 66421|
|Principal Investigator:||Magnus Baumhäkel, MD||University Hospital of the Saarland|
|Principal Investigator:||Michael Böhm, MD||University Hospital of the Saarland|
|Principal Investigator:||Martin Gerber, MD||University Hospital of the Saarland|
|Principal Investigator:||Michael Stöckle, MD||University Hospital of the Saarland|